News >

Long-Term Data Highlight Poor Prognosis With TP53-Mutant MCL

Danielle Ternyila
Published: Friday, Oct 11, 2019

blood cellsPatients with mantle cell lymphoma (MCL) who harbor a TP53 mutation demonstrated a median overall survival (OS) of approximately 4 years compared with patients with wild-type tumors whose median OS had not yet been reached, suggesting that the presence of TP53 mutations directly correlate with OS, according to a 10-year analysis presented at the 2019 European Hematology Association Congress. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication